Supplementary Figure S6 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer

Sheng Ma; Yue Ge; Zequn Lu; Junbiao Zhang; Qin Zhang; Yuzheng Peng; Zirui Xi; Hao Peng; Mengyao Xu; Zezhong Xiong; Yuan Gao; Yanan Wang; Le Li; Chunyu Zhang; Zheng Chao; Tengfei Li; Ruiyun Zhang; Qiang Zhang; David Horne; Baojun Wang; Xu Gao; Xu Zhang; Jianbo Tian; Jing Li; Meng Jin; Gong‐Hong Wei; Zhihua Wang

doi:10.1158/0008-5472.30255299

Key Points

NCOA4 promotes ferroptosis in prostate cancer, indicating a potential therapeutic target.
Integrated analyses identified enhancer variants connected to ferroptosis in prostate cancer.
Multicohort studies provided robust evidence supporting NCOA4's role in ferroptosis.
This research suggests that targeting ferroptosis may enhance precision therapy options for prostate cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Integrated omics analyses and multicohort studies reveal that NCOA4 drives ferroptosis in prostate cancer, suggesting potential for precision therapy.

Abstract

NCOA4 promotes ferroptosis in prostate cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a5b https://doi.org/10.1158/0008-5472.30255299

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S6 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S6 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading